Nenad Petrovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nenad Petrovic has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Inna Sleptsova-Freidrich
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
1 shared publicationKhuyen Gia Hoang
School of Pharmacy and Medical Sciences, University of South Australia, Australia
1 shared publicationMichael Murray
Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, Australia
1 shared publication- Michael Murray
Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, and School of Pharmacy, Faculty of Medicine and Health, University of Sydney, New South Wales, 2006, Australia
1 shared publication - Peter I. Mackenzie
Clinical Pharmacology, College of Medicine and Public Health, Flinders Medical Centre and Flinders University, Adelaide, Australia
1 shared publication Sarah Allison
Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, Australia
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in Microvascular Research
- Vol. 101, 127-134
Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors
- 1 September 2015
- Published by Elsevier in Microvascular Research
- Vol. 101, 127-134
Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors
- 1 August 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 96 (4) , 306-314
Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2
- 1 August 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 96 (4) , 306-314
Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2
- Open Access
- 16 July 2014
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 17 (3) , 439-446
Use of Proton Pump Inhibitors as Adjunct Treatment for Triple-Negative Breast Cancers. An Introductory Study
PURPOSE: Triple negative breast cancers (estrogen, progesterone and human epidermal growth factor 2 (HER2) receptor-negative) are among the most aggressive forms of cancers with limited treatment options. Doxorubicin is one of the agents found in many of the current cancer treatment protocols, although its use is limited by dose-dependent cardiotoxicity. This work investigates one of the ways to suppress cancer growth by inhibiting tumor cell ability to remove acid accumulated during its metabolism by proton pump inhibitor esomeprazole (a drug with extensive clinical use) which could serve as an addition to doxorubicin therapy. METHODS: In this work, we have investigated growth suppression of triple-negative breast cancer cells MDA-MB-468 by esomeprazole and doxorubicin by trypan blue exclusion assay. Measurement of acidification of treated cancer cells was performed using intracellular pH-sensitive probe, BCECF-AM. Finally, expression of gastric type proton pump (H+/K+ ATPase, a target for esomeprazole) on MDA-MB-468 cells was detected by immunofluorescence and Western blotting. RESULTS: We have found that esomeprazole suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. In contrast, esomeprazole did not have significant effect on non-cancerous breast epithelial MCF-10A cells. Esomeprazole increases doxorubicin effects suggesting that dual treatments might be possible. In addition, response of MDA-MB-468 cells to esomeprazole could be mediated by gastric type proton pump (H+/K+ ATPase) in cancer cells contrary to previous beliefs that this proton pump expression is restricted to parietal cells of the stomach epithelia. CONCLUSION: This study provides first evidence that adjunct use of esomeprazole in breast cancer treatment might be a possible to combat adverse effects of doxorubicin and increase its effectiveness. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
- 16 July 2014
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 17 (3) , 439-446
Open AccessUse of Proton Pump Inhibitors as Adjunct Treatment for Triple-Negative Breast Cancers. An Introductory Study
PURPOSE: Triple negative breast cancers (estrogen, progesterone and human epidermal growth factor 2 (HER2) receptor-negative) are among the most aggressive forms of cancers with limited treatment options. Doxorubicin is one of the agents found in many of the current cancer treatment protocols, although its use is limited by dose-dependent cardiotoxicity. This work investigates one of the ways to suppress cancer growth by inhibiting tumor cell ability to remove acid accumulated during its metabolism by proton pump inhibitor esomeprazole (a drug with extensive clinical use) which could serve as an addition to doxorubicin therapy. METHODS: In this work, we have investigated growth suppression of triple-negative breast cancer cells MDA-MB-468 by esomeprazole and doxorubicin by trypan blue exclusion assay. Measurement of acidification of treated cancer cells was performed using intracellular pH-sensitive probe, BCECF-AM. Finally, expression of gastric type proton pump (H+/K+ ATPase, a target for esomeprazole) on MDA-MB-468 cells was detected by immunofluorescence and Western blotting. RESULTS: We have found that esomeprazole suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. In contrast, esomeprazole did not have significant effect on non-cancerous breast epithelial MCF-10A cells. Esomeprazole increases doxorubicin effects suggesting that dual treatments might be possible. In addition, response of MDA-MB-468 cells to esomeprazole could be mediated by gastric type proton pump (H+/K+ ATPase) in cancer cells contrary to previous beliefs that this proton pump expression is restricted to parietal cells of the stomach epithelia. CONCLUSION: This study provides first evidence that adjunct use of esomeprazole in breast cancer treatment might be a possible to combat adverse effects of doxorubicin and increase its effectiveness. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.